References
- Statistics NH. Percentage of angina for adults aged 18 and over, United States, 2019–2022. 2022. Available from: https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html
- Asher MI, Rutter CE, Bissell K, Chiang CY, El Sony A, Ellwood E, Ellwood P, García-Marcos L, Marks GB, Morales E, et al. Worldwide trends in the burden of asthma symptoms in school-aged children: global Asthma Network Phase I cross-sectional study. Lancet. 2021;398(10311):1569–1580. doi: 10.1016/S0140-6736(21)01450-1.
- Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018;15(3):348–356. doi:10.1513/AnnalsATS.201703-259OC.
- National Heart, Lung, and Blood Institute. Asthma: Causes and Triggers. Updated April 17, 2024. Available from: https://www.nhlbi.nih.gov/health/asthma/causes.
- Elward KS. Asthma management guidelines: focused updates for 2020. Am Fam Phys. 2021;104(5):446–447.
- Staff MC. Asthma. Available from: https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660.
- Perez MF, Coutinho MT. An overview of health disparities in asthma. Yale J Biol Med. 2021;94(3):497–507.
- Parker K, Horowitz JM, Brown A, Fry R, Cohn D, Igielnik R. Demographic and economic trends in urban, suburban and rural communities. Pew Research Center. 2018. Available from: https://www.pewresearch.org/wp-content/uploads/sites/20/2018/05/Pew-Research-Center-Community-Type-Full-Report-FINAL.pdf
- Matsui EC. Environmental exposures and asthma morbidity in children living in urban neighborhoods. Allergy. 2014;69(5):553–558. doi:10.1111/all.12361.
- Grant T, Croce E, Matsui EC. Asthma and the social determinants of health. Ann Allergy Asthma Immunol. 2022;128(1):5–11. doi:10.1016/j.anai.2021.10.002.
- Kim Y, Pirritano M, Parrish KM. Determinants of racial and ethnic disparities in utilization of hospital-based care for asthma among Medi-Cal children in Los Angeles. J Asthma. 2022;59(8):1521–1530. doi:10.1080/02770903.2021.1955131.
- McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI.
- Biologics for the management of severe asthma. 2019. Available from: https://www.aaaai.org/tools-for-the-public/conditions-library/asthma/biologics-for-the-management-of-severe-asthma.
- Inselman JW, Jeffery MM, Maddux JT, Shah ND, Rank MA. Trends and disparities in asthma biologic use in the United States. J Allergy Clin Immunol Pract. 2020;8(2):549–554.e1. doi:10.1016/j.jaip.2019.08.024.
- Abbas F, Georas S, Cai X, Khurana S. Asthma biologics: real-world effectiveness, impact of switching biologics, and predictors of response. Ann Allergy Asthma Immunol. 2021;127(6):655–660.e1. doi:10.1016/j.anai.2021.08.416.
- Akenroye AT, Heyward J, Keet C, Alexander GC. Lower use of biologics for the treatment of asthma in publicly insured individuals. J Allergy Clin Immunol Pract. 2021;9(11):3969–3976. doi:10.1016/j.jaip.2021.01.039.
- Gaffney AW, Hawks L, Bor D, White AC, Woolhandler S, McCormick D, Himmelstein DU. National trends and disparities in health care access and coverage among adults with asthma and COPD: 1997–2018. Chest. 2021;159(6):2173–2182. doi:10.1016/j.chest.2021.01.035.
- Gleeson PK, Morales KH, Hvisdas C, LaCava AF, Harhay MO, Rank MA, Apter AJ, Himes BE. Factors associated with asthma biologic prescribing and primary adherence among adults in a large health system. J Allergy Clin Immunol Pract. 2023;11(6):1834–1842.e4. doi:10.1016/j.jaip.2023.03.003.
- Sehanobish E, Ye K, Imam K, Sariahmed K, Kurian J, Patel J, Belletti D, Chung Y, Jariwala S, White A, et al. Elaborate biologic approval process delays care of patients with moderate-to-severe asthma. J Allergy Clin Immunol Glob. 2023;2(2):100076. doi:10.1016/j.jacig.2022.10.007.
- Data USA. Bronx County, NY. 2023. Available from: https://datausa.io/profile/geo/bronx-county-ny#health.
- U.S. Census Bureau. QuickFacts: Bronx County, New York. 2022. Available from: https://www.census.gov/quickfacts/fact/table/bronxcountynewyork/PST045222.
- Sariahmed K, Kurian J, Singh AK, Leyton C, Minuti A, Jerschow E, Arora S, Jariwala SP. Social, political, and economic determinants of access to biologics: a scoping review of structural determinants in the clinical disparities literature. Res Soc Admin Pharm. 2022;18(12):4038–4047. doi:10.1016/j.sapharm.2022.07.047.
- Social Needs Screening Toolit. Health leads. 2018. https://healthleadsusa.org/wp-https://content/uploads/2023/05/Screening_Toolkit_2018.pdf.
- Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible—the neighborhood atlas. N Engl J Med. 2018;378(26):2456–2458. doi:10.1056/NEJMp1802313.
- Research, CFHD. About the neighborhood atlas. 2021. Available from: https://www.neighborhoodatlas.medicine.wisc.edu/.
- Aging N. Demographics by Neighborhood Tabulation Area (NTA). 2020. Available from: https://www.nyc.gov/assets/dfta/downloads/pdf/reports/Demographics_by_NTA.pdf.
- New York City Department of City Planning. Population division. Dynamics of racial/hispanic composition in NYC neighborhoods. ArcGIS StoryMaps. 2023. Available from: https://storymaps.arcgis.com/stories/46a91a58447d4024afd00771eec1dd23.
- Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053.
- Bureau USC. QuickFacts: New York. 2023. Available from: https://www.census.gov/quickfacts/fact/table/NY/INC110221.
- Abbas F, Georas S, Cai X, Khurana S. Asthma biologics: real-world effectiveness, impact of switching biologics, and predictors of response. Annal Allergy Asthma Immunol. 2021;127(6):655–660.e1. doi:10.1016/j.anai.2021.08.416.
- Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. doi:10.1067/mai.2001.117880.
- Gleeson P, Morales K, Hvisdas C, LaCava A, Harhay M, Rank M, Apter A, Himes B. Factors associated with asthma biologic prescribing and adherence among adults in a large multi-hospital health system. J Allergy Clin Immunol. 2023;151(2):AB73. doi:10.1016/j.jaci.2022.12.232.
- Osazuwa-Peters OL, Greiner MA, Oberle A, Oakes M, Thomas SM, Bosworth H. Factors related to biologic adherence and outcomes among moderate-to-severe asthma patients. J Allergy Clin Immunol Pract. 2022;10(9):2355–2366. doi:10.1016/j.jaip.2022.05.022.
- Udemgba C, Sarkaria SK, Gleeson P, Bryant-Stephens T, Ogbogu PU, Khoury P, Apter AJ. New considerations of health disparities within allergy and immunology. J Allergy Clin Immunol. 2023;151(2):314–323. doi:10.1016/j.jaci.2022.11.004.
- Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221.
- Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, Rajput Y. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23–32. doi:10.1080/03007995.2019.1660539.
- Sico IP, Oberle A, Thomas SM, Barsanti T, Egbuonu-Davis L, Kennedy DT, Zullig LL, Bosworth HB. Therapeutic inertia in prescribing biologics for patients with moderate-to-severe asthma. Patient Prefer Adherence. 2021;15:705–712. doi:10.2147/PPA.S303841.